<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126941</url>
  </required_header>
  <id_info>
    <org_study_id>2019 FOR-HYPO</org_study_id>
    <nct_id>NCT04126941</nct_id>
  </id_info>
  <brief_title>Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism</brief_title>
  <acronym>FOR-HYPO</acronym>
  <official_title>Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native
      and active vitamin D, calcium supplementation and sometimes phosphate binders, with the risk
      of long term hypercalciuria, nephrocalcinosis and further renal impairment. The use of
      teriparatide has been reported in adults (daily or bi-daily subcutaneous infusions) and in
      children (rather continuous subcutaneous infusion) as second-line therapy.

      The objective of this study is to obtain efficacy and safety data on the use of teriparatide
      in children with hypoparathyroidism to improve our knowledge of their management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>3 months after treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>1 month after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>6 months after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>12 months after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>3 years after treatment initiation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <description>Patients with hypoparathyroidism treated by teriparatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum calcium concentrations results</intervention_name>
    <description>To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy</description>
    <arm_group_label>Teriparatide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypoPTH (Hypoparathyroidism) treated with teriparatide
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypoparathyroidism

          -  Patients treated with teriparatide

          -  Patients followed in the reference center for calcium and phosphate metabolism
             diseases of Lyon.

          -  For children under 18: patient and parent (s) / parent having been informed of the
             study and having expressed their non-opposition

        Exclusion Criteria:

          -  No social security support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justine BACCHETTA, MD</last_name>
    <phone>4 27 85 61 30</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sacha FLAMMIER, PHD</last_name>
    <phone>4 27 85 66 69</phone>
    <phone_ext>+33</phone_ext>
    <email>sacha.flammier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine BACCHETTA, MD</last_name>
      <phone>4 27 85 61 30</phone>
      <phone_ext>+33</phone_ext>
      <email>justine.bacchetta@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>Teriparatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

